Genentech's BD Exec Spotlights Neuroscience Pipeline
Executive Summary
Thomas Zioncheck, business development executive at Genentech, outlines the company's upcoming R&D goals and early-stage partnering approach outside of oncology. He highlights Genentech's multiple sclerosis portfolio and adds color to its R&D strategy for products targeting Alzheimer's disease and other neurological conditions.
You may also be interested in...
Genentech's Early Cancer Technology Scout On Partnering, Roche Setup & BD Challenges
There is still much more to be learnt about cancer immunology, particularly what drives cancer cell growth, proliferation and resistance mechanisms, says Kevin Sin, Genentech's VP of oncology business development. Speaking to Scrip at the recent BIO-Europe Spring partnering conference, Sin describes Genentech's partnering strategy in oncology and how, almost a decade after the merger, Roche and Genentech are still working collaboratively and competitively to find the best new science in cancer.
Finding Value Left On The Shelf: Karuna Case Study
PureTech’s gamble to take an older Eli Lilly drug off the shelf to redevelop in a new indication paid off. The company aims to replicate this 'Karuna model' in the near future.
Podcast: NodThera On The Role Of The Brain In Driving Chronic Disease
Alan Watt, CEO of NodThera, a clinical-stage biotech developing brain-penetrant NLRP3 inflammasome inhibitors to treat chronic inflammatory diseases, talks to In Vivo about the company’s pipeline and recent data publication in the field of obesity.